GLP-1 prescribing increased faster among adults with serious mental illness than among those without serious mental illness from 2018 to 2024, according to a Sept. 2 study published in JAMA Psychiatry. Here are five things to know:
GLP-1s
More than 450 employees at The Cigna Group have signed a petition challenging the company’s decision to end GLP-1 weight-loss coverage for its workforce. Cigna stopped covering GLP-1s for weight loss through its employee health plan July 1. The company…
More than a dozen experimental obesity drugs are working their way through clinical trials, and the last year has reshuffled the leaderboard: some candidates have advanced into pivotal phase 3 studies, others have won approval overseas and at least one…
Nearly half of adults who started semaglutide (Ozempic, Wegovy) for obesity management discontinued treatment within 12 months, a nationwide cohort study found. Researchers analyzed 157,822 first-time semaglutide users without diabetes in Denmark between Dec. 1, 2022, and Nov. 1, 2024,…
Medicare’s GLP-1 Bridge program is seeing early uptake at major retail pharmacies, with CVS and Walgreens each filling about 100,000 prescriptions less than two months after the program launched in July, according to an Aug. 26 NPR report. “We expected…
Advertisement
Employers are increasingly focused on GLP-1 costs as pharmacy spending continues to rise, according to Business Group on Health’s 2027 Employer Healthcare Strategy Survey. The survey, conducted in June, included 127 employers representing 11 million covered lives. Here are seven…
Nine months after President Donald Trump announced a deal offering states discounted pricing on GLP-1 drugs for Medicaid patients, most states are declining to participate, according to an Aug. 22 Politico report. Only Indiana has publicly signed on, while 29…
Eli Lilly and Novo Nordisk have pursued a multiyear legal and regulatory campaign against compounders and telehealth companies selling unapproved versions of their GLP-1 drugs. Novo has filed 130 federal lawsuits and five challenges with BBB National Programs’ National Advertising…
Emerging research has linked GLP-1 medicines to a lower risk of breast cancer and better outcomes among people diagnosed with the disease. Here are five findings from studies highlighted in an Aug. 20 Breastcancer.org report: All of the studies were…
Novo Nordisk has begun a late-stage trial testing lower doses of its oral Wegovy pill. The placebo-controlled trial, called OASIS 5, began enrolling patients Aug. 12 and will compare two undisclosed lower doses of oral semaglutide with placebo in about…